TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Wolf Haldenstein Adler Freeman & Herz Llp
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately

Telix Pharmaceuticals is facing a potential securities class action lawsuit alleging misrepresentations about its prostate cancer therapeutic candidates and supply chain operations, following an SEC subpoena and subsequent stock price declines.

Insights
TLX   negative

Company experienced significant stock price drops after SEC subpoena, potential misrepresentations about drug pipeline, and receiving a Complete Response Letter from FDA for a renal cancer drug candidate